Does flavopiridol improve response in patients with untreated or relapsed mantle-cell lymphoma?
Flavopiridol shows modest single-agent activity in mantle-cell lymphoma, suggesting it may be useful in combination with other agents or using different schedules.
Flavopiridol given as a daily bolus for 3 consecutive days every 3 weeks has modest activity as a single agent for mantle-cell lymphoma. The number of stable and partial responses that was seen indicates that it is biologically active and may delay progression. Future studies in mantle-cell lymphoma should test this agent with other active agents and using different schedules.
Kouroukis et al. (2003) studied this question.